Literature DB >> 32193903

Clinical Score System to Differentiate Severe Fever with Thrombocytopenia Syndrome Patients from Patients with Scrub Typhus or Hemorrhagic Fever with Renal Syndrome in Korea.

Dae Hyuk Heo1, Yu Min Kang2, Kyoung Ho Song1,3, Jun Won Seo1, Jeong Han Kim1, June Young Chun1, Kang Il Jun4, Chang Kyung Kang5,4, Song Mi Moon1, Pyoeng Gyun Choe5,4, Wan Beom Park5,4, Ji Hwan Bang5,6, Eu Suk Kim1,5, Hong Bin Kim1,5, Sang Won Park5,6, Won Sup Oh2, Nam Joong Kim5,4, Myoung Don Oh5,4.   

Abstract

BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality in East Asia. This study aimed to develop, for primary care providers, a prediction score using initial symptoms and basic laboratory blood tests to differentiate between SFTS and other endemic zoonoses in Korea.
METHODS: Patients aged ≥ 18 years diagnosed with endemic zoonoses during a 3-year period (between January 2015 and December 2017) were retrospectively enrolled from 4 tertiary university hospitals. A prediction score was built based on multivariate logistic regression analyses.
RESULTS: Of 84 patients, 35 with SFTS and 49 with other endemic zoonoses were enrolled. In multivariate logistic regression analysis, independent predictors of SFTS included neurologic symptoms (odds ratio [OR], 12.915; 95% confidence interval [CI], 2.173-76.747), diarrhea (OR, 10.306; 95% CI, 1.588-66.895), leukopenia (< 4,000/mm³) (OR, 19.400; 95% CI, 3.290-114.408), and normal C-reactive protein (< 0.5 mg/dL) (OR, 24.739; 95% CI, 1.812-337.742). We set up a prediction score by assigning one point to each of these four predictors. A score of ≥ 2 had 82.9% sensitivity (95% CI, 71.7%-87.5%) and 95.9% specificity (95% CI, 88.0%-99.2%). The area under the curve of the clinical prediction score was 0.950 (95% CI, 0.903-0.997).
CONCLUSION: This study finding suggests a simple and useful scoring system to predict SFTS in patients with endemic zoonoses. We expect this strategic approach to facilitate early differentiation of SFTS from other endemic zoonoses, especially by primary care providers, and to improve the clinical outcomes.
© 2020 The Korean Academy of Medical Sciences.

Entities:  

Keywords:  Differential Diagnosis; Hemorrhagic Fever with Renal Syndrome; Prediction; Scrub Typhus; Severe Fever with Thrombocytopenia Syndrome

Mesh:

Substances:

Year:  2020        PMID: 32193903      PMCID: PMC7086083          DOI: 10.3346/jkms.2020.35.e77

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


INTRODUCTION

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease caused by the novel bunyavirus, called SFTS virus, which was first reported in China in 20111 and Korea and Japan in 2013.23 The virus is transmitted by ticks such as Haemaphysalis longicornis.1 The clinical manifestations of SFTS are nonspecific and include fever, myalgia, vomiting, and diarrhea. In critically ill patients, multi-organ failure may occur.4 There is no effective antiviral therapy, and the mortality ranges from 6.3% to 30%.56 Because SFTS is a disease with a rapidly progressive deterioration and high mortality rate, early diagnosis is important for survival of patients and preventing transmission of infection.67 Although the number of SFTS cases has increased steadily, with 259 patients with SFTS in 2018, other endemic zoonoses, such as scrub typhus (6,682 patients), hemorrhagic fever with renal syndrome (HFRS) (433), and leptospirosis (118) were more prevalent in Korea.8 Moreover, early clinical manifestations of SFTS are similar to those of other endemic zoonoses; therefore, SFTS needs to be differentiated from these diseases. Although the quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay is a reliable method for early diagnosis of SFTS,9 this test could not be performed by most primary care providers at local clinics. Therefore, we aimed to derive a clinical prediction scoring system with initial symptoms and basic laboratory blood tests that could be useful for primary care providers to differentiate SFTS from other endemic zoonoses. We also evaluated the predictability of the score, reassessed 2 days after admission in patients with low probability of SFTS.

METHODS

Patients and data collection

Patients aged 18 years or older diagnosed with endemic zoonoses during the 3-year period from January 2015 to December 2017 were enrolled from 4 university hospitals in Korea: Seoul National University Bundang Hospital (1,300 beds), Boramae Medical Center (800 beds), Seoul National University Hospital (1,700 beds), and Kangwon National University Hospital (600 beds). Endemic zoonoses included SFTS, scrub typhus, HFRS, leptospirosis, Q fever, and human granulocytic anaplasmosis (HGA). All patients with a diagnosis code and/or confirmatory test results of endemic zoonoses were screened. SFTS was confirmed by detecting the M segment gene of the viral ribonucleic acid (RNA) with RT-PCR as described in a previous study.10 Scrub typhus was diagnosed by a single titer ≥ 1:16011 or a ≥ 4-fold rise in indirect immunofluorescent assay (IFA) titer in paired serum samples. HFRS was diagnosed by a single titer ≥ 1:80, ≥ 4-fold rise in IFA titer in paired serum samples, or positive RT-PCR test. Considering the incidence and importance of these endemic zoonoses in Korea, we included only the patients with all three of the above results in this study. Leptospirosis was diagnosed by ≥ 4-fold rise in IFA titer in paired serum samples or an antibody titer ≥ 1:800 in one serum sample by the microscopic agglutination test. Q fever was diagnosed by ≥ 4-fold rise an antiphase II antigen immunoglobulin G titer in paired serum samples. HGA was diagnosed by ≥ 4-fold rise in IFA titer in paired serum samples or positive PCR test. We excluded patients with bacteremia or co-infections between endemic zoonoses. We retrospectively reviewed the demographic and clinical data of the patients, including age, gender, occupation, comorbidities, presence of symptoms, and laboratory findings, to analyze the differentiating factors between SFTS and other endemic zoonoses. Neurologic symptoms included altered mentality, for which Glasgow coma scale score is < 15, and tremor, motor weakness, and dysarthria, which were based on the information in the physician or nurse's medical records. Diarrhea was defined as three or more unformed stools per day, and we also considered that diarrhea was present when the attending physician described diarrhea symptoms in the patient's medical record. Leukopenia was defined as white blood cell count < 4,000/mm3. Thrombocytopenia was defined as blood platelet count < 150 × 103/mm3. Normal C-reactive protein (CRP) was defined as < 0.5 mg/dL.

Statistical analysis

Categorical variables were compared using χ2 or Fisher's exact tests, and continuous variables were compared using t-test or Mann-Whitney U test. Multivariate logistic regression analysis was performed using the significant differentiating factors (P < 0.05) between SFTS and other endemic zoonoses in univariate analysis and adjusted for the duration from the onset of illness to the initial presentation. We excluded some variables that could be influenced by recall bias or had insufficient description (e.g., insect bite wound) from the multivariate analysis. For possible overlapping variables (e.g., anemia and bleeding), we constructed separate models. Variables without all patients' data were excluded from multivariate regression model. The prediction score for SFTS was built based on the final multivariate regression model. The receiver operating characteristic (ROC) curve was constructed for scoring model. Statistical analyses were performed using SPSS for Windows (version 18 software package; SPSS, Inc., Chicago, IL, USA).

Ethics statement

This study was approved by the Institutional Review Board (IRB) of Seoul National University Bundang Hospital (B-1801/445-112), which waived the need to obtain informed consent from the patients. All the other institutions participating in this study also obtained approvals from their IRBs. All clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.

RESULTS

A total of 202 patients were diagnosed with endemic zoonoses clinically and/or by laboratory tests during the 3-year period including 49 patients with SFTS, 132 with scrub typhus, 18 with HFRS, 2 with Q fever, and 1 with leptospirosis. Of these, 118 patients (without the test results for the following three, SFTS, scrub typhus, and HFRS, or with other bacterial infection) were excluded. Finally, 84 patients including 35 with SFTS and 49 with other endemic zoonoses (40 scrub typhus and 9 HFRS) were enrolled in this study (Supplementary Fig. 1). None of the patients clinically diagnosed with leptospirosis, Q fever, or HGA met the enrollment criteria. Patients' demographic and clinical characteristics are described in Table 1. At the initial presentation, diarrhea and neurologic symptoms were more common in SFTS patients than in other endemic zoonoses patients. In the laboratory findings, the elevation of aspartate aminotransferase (AST), creatinine kinase, and ferritin were also more common in SFTS patients than in others. White blood cell (WBC), CRP, and procalcitonin were rarely elevated in SFTS. In addition, on comparing the three diseases, younger men were more common in the HFRS group, and no rash was observed. Diarrhea, neurologic symptoms, and normal CRP were more common in the SFTS group (Supplementary Table 1).
Table 1

Comparison of patients' baseline clinical characteristics and laboratory results between SFTS and other endemic zoonoses

VariablesSFTS (n = 35)Other endemic zoonosesa (n = 49)P value
Age, yr64.5 ± 11.062.5 ± 19.70.640
Gender, men23 (65.7)25 (51.0)0.180
Occupation
Farmers14 (40.0)20 (40.8)0.940
Underlying disease
Diabetes7 (20.0)6 (12.2)0.333
Cerebrovascular disease1 (2.9)2 (4.1)1.000
Chronic kidney disease0 (0)1 (2.0)1.000
Chronic lung disease0 (0)2 (4.1)0.508
Chronic liver disease0 (0)1 (2.0)1.000
Solid tumor0 (0)3 (6.1)0.262
Onset to admission, day5.7 ± 2.55.7 ± 3.20.996
Clinical characteristics
Fever30 (85.7)41 (85.4)0.970
Rash7 (20.0)15 (30.6)0.275
Insect bite wound11 (31.4)26 (53.1)0.049
Lymphadenopathy5 (14.3)1 (2.0)0.078
Myalgia21 (60.0)33 (67.3)0.488
Nausea/vomiting14 (40.0)13 (26.5)0.193
Diarrhea19 (54.3)6 (12.2)< 0.001
Abdominal pain13 (37.1)13 (26.5)0.300
Bleeding9 (25.7)5 (10.2)0.060
Cough/sputum/dyspnea10 (28.6)20 (40.8)0.248
Headache13 (37.1)12 (24.5)0.211
Neurologic symptoms21 (60.0)8 (16.3)< 0.001
Leukopenia, WBC < 4,000/mm328 (80.0)5 (10.2)< 0.001
Leukocytosis, WBC > 10,000/mm31 (2.9)17 (34.7)< 0.001
WBC, /mm33,095 ± 2,10110,056 ± 7,867< 0.001
Neutrophil, %54 ± 1971 ± 16< 0.001
Lymphocyte, %32 ± 1518 ± 11< 0.001
Monocyte, %8.5 ± 8.57.4 ± 6.70.676
Anemia, hemoglobin < 11 g/dL0 (0)6 (12.2)0.038
Hemoglobin, g/dL14.2 ± 1.513.3 ± 2.70.007
Thrombocytopenia, platelet < 150 × 103/mm333 (94.3)40 (81.6)0.111
Platelet, × 103/mm378 ± 4097 ± 640.276
PT, INR1.01 ± 0.121.10 ± 0.180.004
aPTT, sec57 ± 2144 ± 18< 0.001
Fibrinogen, mg/dLb261 ± 52345 ± 1260.004
Abnormal LFT, AST or ALT > 40 IU/L31 (88.6)47 (95.9)0.229
AST, IU/L530 ± 899147 ± 1750.014
ALT, IU/L161 ± 16794 ± 1020.142
ALP, IU/L119 ± 106128 ± 710.013
Total bilirubin, mg/dL0.5 ± 0.21.0 ± 0.8< 0.001
BUN, mg/dL22.3 ± 18.324.5 ± 18.40.295
Creatinine, mg/dL1.0 ± 0.51.2 ± 1.20.967
ESR, mm/hrb10 ± 1128 ± 250.267
Normal CRP, < 0.5 mg/dL17 (48.6)2 (4.1)< 0.001
CRP, mg/dL1.40 ± 1.7711.13 ± 7.75< 0.001
LDH, IU/Lb1,297 ± 1,229833 ± 4260.205
Creatine kinase, IU/Lb1,249 ± 1,502187 ± 354< 0.001
Ferritin, ng/mLb14,942 ± 26,706324 ± 370.026
Procalcitonin, ng/mLb0.16 ± 0.052.97 ± 5.260.001

Data are presented as mean ± standard deviation or number (%).

SFTS = severe fever with thrombocytopenia syndrome, WBC = white blood cell, PT = prothrombin time, INR = international normalized ratio, aPTT = activated partial thromboplastin time, LFT = liver function test, AST = aspartate aminotransferase, ALT = alanine aminotransferase, IU =international unit, ALP = alkaline phosphatase, BUN =blood urea nitrogen, ESR =erythrocyte sedimentation rate, CRP = C-reactive protein, LDH = lactate dehydrogenase.

aNumber of patients with other endemic zoonoses: scrub typhus 40, hemorrhagic fever with renal syndrome 9; bNumber of patients with the biomarkers results: Fibrinogen (SFTS 19, other endemic zoonoses 20), ESR (SFTS 2, other endemic zoonoses 4), LDH (SFTS 28, other endemic zoonoses 32), Creatinine kinase (SFTS 34, other endemic zoonoses 42), Ferritin (SFTS 11, other endemic zoonoses 2), and Procalcitonin (SFTS 4, other endemic zoonoses 11).

Data are presented as mean ± standard deviation or number (%). SFTS = severe fever with thrombocytopenia syndrome, WBC = white blood cell, PT = prothrombin time, INR = international normalized ratio, aPTT = activated partial thromboplastin time, LFT = liver function test, AST = aspartate aminotransferase, ALT = alanine aminotransferase, IU =international unit, ALP = alkaline phosphatase, BUN =blood urea nitrogen, ESR =erythrocyte sedimentation rate, CRP = C-reactive protein, LDH = lactate dehydrogenase. aNumber of patients with other endemic zoonoses: scrub typhus 40, hemorrhagic fever with renal syndrome 9; bNumber of patients with the biomarkers results: Fibrinogen (SFTS 19, other endemic zoonoses 20), ESR (SFTS 2, other endemic zoonoses 4), LDH (SFTS 28, other endemic zoonoses 32), Creatinine kinase (SFTS 34, other endemic zoonoses 42), Ferritin (SFTS 11, other endemic zoonoses 2), and Procalcitonin (SFTS 4, other endemic zoonoses 11). In the multivariate logistic regression analysis, neurologic symptoms, diarrhea, leukopenia, and normal CRP were significantly associated with SFTS rather than with other endemic zoonoses (Table 2).
Table 2

Results of univariate and multivariate logistic regression analyses of the clinical and laboratory factors associated with SFTS

VariablesOR95% CIP value
Univariate
Age1.0070.981–1.0350.590
Gender, men0.5430.222–1.3300.182
Farmers1.0340.427–2.5050.940
Diabetes1.7920.545–5.8880.337
Cerebrovascular disease0.6910.060–7.9350.767
Onset of illness0.9980.859–1.1590.979
Fever1.0240.296–3.5420.970
Rash0.5670.203–1.5830.278
Insect bite wound0.4050.164–1.0050.051
Lymphadenopathy8.0000.891–71.8370.063
Myalgia0.7270.295–1.7930.489
Nausea/vomiting1.8460.731–4.6660.195
Diarrhea8.5102.883–25.124< 0.001
Abdominal pain1.6360.643–4.1640.301
Bleeding3.0460.921–10.0720.068
Cough/sputum/dyspnea0.5800.229–1.4680.250
Headache1.8220.708–4.6900.214
Neurologic symptoms7.6872.785–21.223< 0.001
Leukopenia35.20010.170–121.832< 0.001
Leukocytosis0.0550.007–0.4400.006
WBC0.9990.999–1.000< 0.001
Neutrophil0.9470.920–0.976< 0.001
Lymphocyte1.0791.037–1.123< 0.001
Monocyte1.0190.962–1.0790.529
Hemoglobin1.1950.974–1.4650.088
Thrombocytopenia3.7120.750–18.3880.108
Platelet0.9940.985–1.0020.132
PT0.0060–0.3820.015
aPTT1.0381.009–1.0690.011
Fibrinogen0.9910.983–0.9990.020
Abnormal LFT0.3300.057–1.9110.216
AST1.0031.001–1.0050.013
ALT1.0041.000–1.0080.041
ALP0.9990.994–1.0040.667
Total bilirubin0.0380.006–0.234< 0.001
BUN0.9930.969–1.0180.588
Creatinine0.7980.479–1.3310.387
ESR0.9230.775–1.0990.367
Normal CRP22.1944.652–105.899< 0.001
CRP0.5720.433–0.756< 0.001
LDH1.0011.000–1.0020.077
Creatine kinase1.0021.001–1.0030.003
Ferritin1.1770.010–141.9330.947
Multivariate
Neurologic symptoms12.9152.173–76.7470.005
Diarrhea10.3061.588–66.8950.015
Bleeding1.8480.205–16.6360.584
Leukopenia19.4003.290–114.4080.001
Normal CRP24.7391.812–337.7420.016
Onset of illness0.8550.631–1.1600.315

SFTS = severe fever with thrombocytopenia syndrome, OR = odds ratio, CI = confidence interval, WBC = white blood cell, PT = prothrombin time, aPTT = activated partial thromboplastin time, LFT = liver function test, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALP = alkaline phosphatase, BUN = blood urea nitrogen, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, LDH = lactate dehydrogenase.

SFTS = severe fever with thrombocytopenia syndrome, OR = odds ratio, CI = confidence interval, WBC = white blood cell, PT = prothrombin time, aPTT = activated partial thromboplastin time, LFT = liver function test, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALP = alkaline phosphatase, BUN = blood urea nitrogen, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, LDH = lactate dehydrogenase. A prediction score for SFTS in comparison with other endemic zoonoses was generated using the combination of those 4 parameters (using 1 point each for neurologic symptoms, diarrhea, leukopenia, and normal CRP) and the total sum ranged from 0 to 4. On the ROC curve obtained for the model, the optimal cut-off was ≥ 2 points. A score of ≥ 2 had 82.9% sensitivity (95% confidence interval [CI], 71.7%–87.5%) and 95.9% specificity (95% CI, 88.0%–99.2%) for SFTS with ROC area under the curve of 0.950 (95% CI, 0.903–0.997) (Table 3 and Fig. 1).
Table 3

Diagnostic performance of the SFTS prediction score systema

Cut-offSensitivity (95% CI)Specificity (95% CI)PPV (95% CI)NPV (95% CI)LR+ (95% CI)LR− (95% CI)
10.971 (0.857–0.999)0.612 (0.531–0.632)0.642 (0.566–0.659)0.968 (0.839–0.998)2.505 (1.828–2.710)0.047 (0.002–0.268)
20.829 (0.717–0.875)0.959 (0.880–0.992)0.935 (0.810–0.988)0.887 (0.813–0.918)20.300 (5.966–116.491)0.179 (0.126–0.321)
30.429 (0.330–0.429)1.000 (0.930–1.000)1.000 (0.770–1.000)0.710 (0.660–0.710)NA0.571 (0.571–0.721)
40.200 (0.116–0.200)1.000 (0.940–1.000)1.000 (0.579–1.000)0.636 (0.598–0.636)NA0.800 (0.800–0.941)

SFTS = severe fever with thrombocytopenia syndrome, CI = confidence interval, PPV = positive predictive value, NPV = negative predictive value, LR+ = positive likelihood ratio, LR− = negative likelihood ratio, NA = not available.

aPrediction score system = (1 × neurologic symptoms) + (1 × diarrhea) + (1 ×leukopenia) + (1 × normal CRP).

Fig. 1

ROC curve of the clinical prediction score for SFTS in patients with endemic zoonoses.

ROC = receiver operating characteristic, SFTS = severe fever with thrombocytopenia syndrome.

SFTS = severe fever with thrombocytopenia syndrome, CI = confidence interval, PPV = positive predictive value, NPV = negative predictive value, LR+ = positive likelihood ratio, LR− = negative likelihood ratio, NA = not available. aPrediction score system = (1 × neurologic symptoms) + (1 × diarrhea) + (1 ×leukopenia) + (1 × normal CRP).

ROC curve of the clinical prediction score for SFTS in patients with endemic zoonoses.

ROC = receiver operating characteristic, SFTS = severe fever with thrombocytopenia syndrome. When we applied this prediction score according to the cut-off ≥ 2, 29 patients had SFTS and 2 patients had other endemic zoonoses (Supplementary Fig. 1). Among 53 patients with a prediction score of 0 or 1, 27 patients had clinical data on the 4 parameters 2 days after admission. Of the 22 patients with other endemic zoonoses and a score of 0 or 1, only 4 patients had diarrhea, and none had neurologic symptoms, leukopenia, or normal CRP. A score ≥ 2 had 100.0% positive predictive value (95% CI, 55.0%–100.0%) (Supplementary Table 2).

DISCUSSION

The present study identified the predictors of SFTS and suggested a clinical scoring system to distinguish SFTS patients from patients with other endemic zoonoses. This system consists of easily applicable clinical parameters, including neurologic symptoms, diarrhea, leukopenia, and normal CRP. This scoring system would be useful for early differentiation of SFTS from other endemic zoonoses. SFTS is already an endemic disease in Korea. Han et al.12 reported an SFTS virus seroprevalence of 4.1% among residents of rural areas in Korea. Most SFTS cases occur from April to November in Korea.6 Scrub typhus and HFRS are common zoonotic diseases in Korea, and are prevalent during autumn. Most of the scrub typhus cases occur between October and November.13 Similarly, HFRS predominantly occurs during the last quarter of the calendar year.14 It is important to differentiate between SFTS and these endemic zoonoses because of their overlapping epidemic seasons. Recently, two studies addressing the differentiation of SFTS from scrub typhus were published.1516 In particular, Park et al.16 proposed a prediction scoring tool to differentiate SFTS from eschar- or skin rash- negative scrub typhus, as it involves diagnostic uncertainty. Furthermore, there has been a report of the usefulness of ferritin as a diagnostic marker to distinguish between SFTS and bacteremia with thrombocytopenia.17 However, there was no previous study that has differentiated SFTS from other endemic zoonoses in Korea. Our clinical score system to predict SFTS used four variables (neurologic symptoms, diarrhea, leukopenia, and normal CRP), which could easily be available in the primary care settings. Although no specific therapy is available for SFTS, and symptomatic and supportive care is the mainstay of treatment,5 several rescue therapies such as ribavirin and plasma exchange18 or intravenous immunoglobulin and corticosteroid19 may be effective in treating rapidly progressive SFTS. Our clinical score system could help clinicians to stratify the patients so that they can decide on whether to try these therapies or make an early referral, particularly in primary care settings.16 However, SFTS can spread via human-to-human transmission through blood contact, unlike other endemic zoonoses including scrub typhus.20 Kim et al.21 reported in Korea that of the 27 healthcare workers who had contact with a severely ill SFTS patient, the 4 who were involved in cardiopulmonary resuscitation were diagnosed with SFTS via seroconversion. Using our clinical score system could facilitate early referral of patients suspected of having SFTS to the tertiary hospital, with possible consideration of nosocomial transmission of SFTS, pending the availability of the confirmatory test result. This study has several limitations. First, although this study included endemic zoonoses in Korea other than scrub typhus or HFRS, such as leptospirosis, Q fever, or HGA, no patient with these diseases met the enrollment criteria. We included 6 HFRS patients diagnosed with a single high titer. However, incorrect diagnosis was not probable as these patients not only had positive serologic results but also had clinical manifestations and an exposure history relevant to HFRS. Second, there have been recent reports of co-infection of SFTS with other zoonoses.2223 The patients with all three (SFTS, scrub typhus, and HFRS) test results were enrolled; thus, it is likely that co-infected cases occurred among those patients that were excluded from this study. We also excluded bacteremia from this study, but some types of bacteremia may be associated with endemic zoonoses. Although we excluded such co-infections to develop a clear predictive scoring system, further study is needed to determine how to distinguish co-infected cases from others. Third, the comparative group did not contain a homogenous population. However, clinicians need a prediction tool to differentiate severe disease among heterogenous populations, and the results of this study confirm the unique clinical findings of SFTS, which may be useful for primary care providers. Finally, we planned to re-evaluate for the likelihood of SFTS 2 days after admission in patients with low predictive scores at the time of admission. However, we could only apply the prediction score 2 days after admission in 27 patients; this was due to the lack of clinical information. Thus, we could not reach a conclusion from this study. Prospective validation study of this prediction score at the time of admission and a study to evaluate the usefulness of early reassessment for SFTS are warranted. In summary, our study suggests a simple and useful scoring system to predict SFTS in patients suspected of having endemic zoonoses in Korea. We expect that this strategic approach would be helpful for primary care providers in early differentiation of SFTS from other endemic zoonoses and for improving the clinical outcomes in patients with SFTS.
  22 in total

1.  Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid.

Authors:  Uh Jin Kim; Dong-Min Kim; Joon Hwan Ahn; Seung-Ji Kang; Hee-Chang Jang; Kyung-Hwa Park; Sook In Jung
Journal:  Antivir Ther       Date:  2016-02-17

2.  A serosurvey of Orientia tsutsugamushi from patients with scrub typhus.

Authors:  D M Kim; Y-M Lee; J-H Back; T Y Yang; J H Lee; H-J Song; S-K Shim; K-J Hwang; M-Y Park
Journal:  Clin Microbiol Infect       Date:  2009-09-23       Impact factor: 8.067

3.  Nosocomial transmission of severe fever with thrombocytopenia syndrome in Korea.

Authors:  Won Young Kim; WooYoung Choi; Sun-Whan Park; Eun Byeol Wang; Won-Ja Lee; Youngmee Jee; Kyoung Soo Lim; Hyun-Jung Lee; Sun-Mi Kim; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Clin Infect Dis       Date:  2015-02-18       Impact factor: 9.079

4.  Mixed Infection with Severe Fever with Thrombocytopenia Syndrome Virus and Two Genotypes of Scrub Typhus in a Patient, South Korea, 2017.

Authors:  Jeong Rae Yoo; Sang Taek Heo; Ji-Hoon Kang; Dahee Park; Jeong Soon Kim; Jeong Hoon Bae; Jong Jin Woo; Suhyun Kim; Keun Hwa Lee
Journal:  Am J Trop Med Hyg       Date:  2018-06-21       Impact factor: 2.345

5.  Differentiation of Severe Fever With Thrombocytopenia Syndrome From Scrub Typhus.

Authors:  Min-Chul Kim; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Clin Infect Dis       Date:  2018-05-02       Impact factor: 9.079

6.  Severe Fever with Thrombocytopenia Syndrome in Patients Suspected of Having Scrub Typhus.

Authors:  Yu Mi Wi; Hye In Woo; Dahee Park; Keun Hwa Lee; Cheol-In Kang; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song
Journal:  Emerg Infect Dis       Date:  2016-11       Impact factor: 6.883

7.  Hyperferritinemia as a Diagnostic Marker for Severe Fever with Thrombocytopenia Syndrome.

Authors:  Uh Jin Kim; Tae Hoon Oh; Bansuk Kim; Seong Eun Kim; Seung-Ji Kang; Kyung-Hwa Park; Sook-In Jung; Hee-Chang Jang
Journal:  Dis Markers       Date:  2017-02-28       Impact factor: 3.434

8.  Rapid increase of scrub typhus, South Korea, 2001-2006.

Authors:  Sun Seog Kweon; Jin Su Choi; Hyun Sul Lim; Jang Rak Kim; Keon Yeop Kim; So Yeon Ryu; Hyo Soon Yoo; Ok Park
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

9.  Epidemiology of hemorrhagic fever with renal syndrome in Korea, 2001-2010.

Authors:  Soo-Han Lee; Byung-Hyun Chung; Won-Chang Lee; In-Soo Choi
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

10.  The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan.

Authors:  Toru Takahashi; Ken Maeda; Tadaki Suzuki; Aki Ishido; Toru Shigeoka; Takayuki Tominaga; Toshiaki Kamei; Masahiro Honda; Daisuke Ninomiya; Takenori Sakai; Takanori Senba; Shozo Kaneyuki; Shota Sakaguchi; Akira Satoh; Takanori Hosokawa; Yojiro Kawabe; Shintaro Kurihara; Koichi Izumikawa; Shigeru Kohno; Taichi Azuma; Koichiro Suemori; Masaki Yasukawa; Tetsuya Mizutani; Tsutomu Omatsu; Yukie Katayama; Masaharu Miyahara; Masahito Ijuin; Kazuko Doi; Masaru Okuda; Kazunori Umeki; Tomoya Saito; Kazuko Fukushima; Kensuke Nakajima; Tomoki Yoshikawa; Hideki Tani; Shuetsu Fukushi; Aiko Fukuma; Momoko Ogata; Masayuki Shimojima; Noriko Nakajima; Noriyo Nagata; Harutaka Katano; Hitomi Fukumoto; Yuko Sato; Hideki Hasegawa; Takuya Yamagishi; Kazunori Oishi; Ichiro Kurane; Shigeru Morikawa; Masayuki Saijo
Journal:  J Infect Dis       Date:  2013-11-14       Impact factor: 5.226

View more
  1 in total

1.  Clinical Differentiation of Severe Fever with Thrombocytopenia Syndrome from Japanese Spotted Fever.

Authors:  Nana Nakada; Kazuko Yamamoto; Moe Tanaka; Hiroki Ashizawa; Masataka Yoshida; Asuka Umemura; Yuichi Fukuda; Shungo Katoh; Makoto Sumiyoshi; Satoshi Mihara; Tsutomu Kobayashi; Yuya Ito; Nobuyuki Ashizawa; Kazuaki Takeda; Shotaro Ide; Naoki Iwanaga; Takahiro Takazono; Masato Tashiro; Takeshi Tanaka; Seiko Nakamichi; Konosuke Morimoto; Koya Ariyoshi; Kouichi Morita; Shintaro Kurihara; Katsunori Yanagihara; Akitsugu Furumoto; Koichi Izumikawa; Hiroshi Mukae
Journal:  Viruses       Date:  2022-08-18       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.